A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer (VICTORIA)
Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy
Sponsor: Pierre Fabre Medicament
Terminated
Study was stopped before progressive disease or death of alive subjects.
Other terminated trials from Pierre Fabre Medicament
Other Advanced Breast Cancer trials with similar outcome
A PHASE3 clinical study on Advanced Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Pierre Fabre Medicament and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pierre Fabre Medicament
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.